The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
August 21st 2025
A recent study highlights that hearing aids significantly lower dementia risk in younger patients with hearing loss, emphasizing the need for early intervention.
SAGE and BrainTest for Cognitive Assessment and Clinical Trial Enrollment: Douglas Scharre, MD
January 12th 2022The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed benefits of both the pen-and-paper and digital assessments. [WATCH TIME: 7 minutes]
CMS Releases Proposed Decision for Aducanumab Coverage in Alzheimer Disease
January 11th 2022The Centers for Medicare and Medicaid Services issued a proposed decision memo detailing the coverage criteria for patients with Alzheimer disease to be covered by the federal health insurance platform when administered aducanumab (Aduhelm; Biogen).
Development of SAGE for Early Dementia Detection: Douglas Scharre, MD
January 11th 2022The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed motivations behind creating the pen-and-paper test, as well as its digital companion. [WATCH TIME: 2 minutes]
Next Steps in Understanding Cognitive Decline in Aging MS: Dejan Jakimovski, MD, PhD
January 11th 2022The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]
Monoclonal Antibodies in Development for Alzheimer Disease: Anton Porsteinsson, MD
January 7th 2022The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester offered an extensive overview of 3 monoclonal antibodies in development for Alzheimer disease. [WATCH TIME: 9 minutes]
Eliminating Wasteful Costs in Alzheimer Drug Development: Jeffrey Cummings, MD, ScD
January 5th 2022The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success. [WATCH TIME: 4 minutes]